Abstract
The future of (89)Zr-based immuno-PET is reliant upon the development of new chelators with improved stability compared to the currently used deferoxamine (DFO). Herein, we report the evaluation of the octadentate molecule DFO-HOPO (3) as a suitable chelator for (89)Zr and a more stable alternative to DFO. The molecule showed good potential for the future development of a DFO-HOPO-based bifunctional chelator (BFC) for the radiolabelling of biomolecules with (89)Zr. This work broadens the selection of available chelators for (89)Zr in search of improved successors to DFO for clinical (89)Zr-immuno-PET.